Diagnostic and treatment algorithm for chronic nodular prurigo - 09/01/20
Abstract |
Chronic nodular prurigo (CNPG) is a subtype of chronic prurigo, also called prurigo nodularis, and a chronic skin condition characterized by intensely pruritic nodular lesions. Although the exact cause of CNPG is unknown, it appears to result from a repetitive itch-scratch cycle induced by neuronal sensitization to chronic pruritus. CNPG is associated with an underlying dermatologic condition in about half of patients, and it can also be attributed to systemic, neurologic, psychogenic, or unknown causes. For most patients, multiple underlying causes are identified. Patients with CNPG often experience impaired quality of life, sleep disturbance, anxiety, and depression. To encourage consistent and accurate diagnosis and treatment of CNPG across regions, we are proposing a diagnostic and treatment algorithm that includes initial assessment of core symptoms, detailed dermatologic history and clinical examination, patient-reported outcomes, diagnostic workup, and recommended therapies. This information is supplemented with photographs to illustrate clinical appearance and disease severity. Because CNPG is often multifactorial and it can take months to years for lesions to heal, interdisciplinary cooperation and long-term management are important.
Le texte complet de cet article est disponible en PDF.Key words : algorithm, chronic nodular prurigo, diagnosis, prurigo nodularis, prurigo scoring, prurigo severity, treatment
Abbreviations used : CNPG, DLQI, IL, NK1R, NRS, VAS
Plan
Funding sources: Supported by Menlo Therapeutics Inc. |
|
Disclosure: Dr HF Ständer is a member of scientific advisory boards and is a consultant for Menlo Therapeutics, Leo, Novartis, and Sanofi-Aventis. Dr Elmariah serves as a scientific advisor to Menlo Therapeutics, AOBiome, and Trevi Therapeutics. Dr Spellman was employed by Menlo Therapeutics Inc. Dr. S Ständer is a principal investigator for Dermasence, Galderma, Kiniksa, Menlo Therapeutics, Trevi Therapeutics, Novartis, and Vanda and is a member of scientific advisory boards and a consultant for Almirall, Astellas, Beiersdorf, Celgene, Galderma, Kiniksa, Kneipp, Maruho, Menlo Therapeutics, NeRRe Therapeutics, Novartis, Sanofi, Sienna, and Trevi Therapeutics. Dr Zeidler has no conflict of interest to declare. |
Vol 82 - N° 2
P. 460-468 - février 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?